COMP <GO>
TEVA vs MRK // PIOTROSKI F-SCORE QUALITY
Teva Pharmaceutical Industries Limited (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: TEVA 4
— MRK 11
▲ PIOTROSKI F-SCORE QUALITY LEADER: TEVA
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 74.80% | -23.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 20.70% | -11.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 15.3x | +5.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 3.42% | -1.61 | MRK | /fcf-yield <GO> |
| Operating Margin | 12.50% | 34.30% | -21.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 28.10% | -19.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 1.30% | +3.00 | TEVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 5.19 | -4.17 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | TEVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.7 | 56.9 | +6.82 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 18.4x | +13.50 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $361.02B | -$312.70B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | MRK REV | TEVA GROSS % | MRK GROSS % | TEVA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $65.01B | 51.8% | 74.8% | $872.4M | $12.36B |
| FY 2024 | $16.54B | $64.17B | 48.7% | 76.3% | $502.5M | $18.10B |
| FY 2023 | $15.85B | $60.12B | 44.0% | 44.0% | $654.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
MRK // BETA 0.92